Advertisement


William J. Gradishar, MD, on Innovating Pathways for Patient Self-Management in Breast Cancer

NCCN 2020 Virtual Annual Conference

Advertisement

William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the “4R Model” (Right Information, Care, Patient, and Time) which has proved to be a promising method for patient self-management. Patient care sequence plans markedly improved several aspects of patient self-management, as well as delivery of multimodality care (Abstract BPI20-017).



Related Videos

Solid Tumors

Hope S. Rugo, MD, on Talazoparib for Advanced Solid Tumors: Reduced Hospitalization and Supportive Care

Hope S. Rugo, MD, of the University of California, San Francisco, discusses an integrated analysis of five clinical trials, in phases I through III, for a variety of advanced...

Issues in Oncology
Symptom Management

Karen Wonders, PhD, on Benefits of Exercise During Cancer Treatment

Karen Wonders, PhD, of Wright State University, discusses the safety and efficacy of exercise during cancer treatment in minimizing toxicities and addressing the short- and l...

Breast Cancer

Elizabeth Reed, MD, on Helping Providers in Rural Areas Meet the Needs of Younger Patients With Breast Cancer

Elizabeth Reed, MD, of the University of Nebraska Medical Center Fred & Pamela Buffett Cancer Center, talks about how she and her team sought to help rural oncology provi...

Head and Neck Cancer
Survivorship

Pam Baker DeGuzman, PhD, on Assessing Distress During Telemedicine Visits With Rural Survivors of Head and Neck Cancer

Pam Baker DeGuzman, PhD, of the University of Virginia School of Nursing, discusses her study findings on the use of the NCCN Distress Thermometer, which identified and addre...

Breast Cancer

Sara A. Hurvitz, MD, on Talazoparib vs Chemotherapy for Breast Cancer: Results From the EMBRACA Trial

Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses racial differences in self-reported outcomes of patients with HER2-negative, locally advanced or ...

Advertisement

Advertisement



Advertisement